1 dose DALVANCE® demonstrated

Proven efficacy against key ABSSSI pathogens, including MRSA

Early clinical response rates at 48 to 72 hours against MRSA1

Percentage of Patients With 20% or Greater Reduction in Lesion Size at 48 to 72 Hours*

Demonstrated clinical success at Days 26 to 30 against MRSA1

Percentage of Patients With Clinical Success at Days 26 to 30*

*Efficacy outcome by baseline pathogen based on primary endpoint.

Proven Gram-positive efficacy against common pathogens in ABSSSI

DALVANCE covers the most common Gram-positive pathogens1

  ≥20% Reduction in Lesion Size
at 48 to 72 Hours
Clinical Success 
at Days 26 to 30
  DALVANCE
1 DOSE
DALVANCE
2 DOSE
DALVANCE
1 DOSE
DALVANCE
2 DOSE
Baseline pathogen % (n/N) % (n/N) % (n/N) % (n/N)
Staphylococcus aureus 88.5 (123/139) 85.3 (133/156) 89.2 (124/139) 89.7 (140/156)
MSSA 89.3 (92/103) 89.6 (89/96) 90.3 (93/103) 89.6 (86/96)
MRSA 86.1 (31/36) 78.7 (48/61) 86.1 (31/36) 90.2 (55/61)
Streptococcus agalactiae 100.0 (6/6) 66.7 (4/6) 83.3 (5/6) 83.3 (5/6)
Streptococcus anginosus group 93.9 (31/33) 100.0 (19/19) 87.9 (29/33) 89.5 (17/19)
Streptococcus pyogenes 100.0 (14/14) 81.8 (18/22) 92.9 (13/14) 86.4 (19/22)
Enterococcus faecalis 100.0 (4/4) 80.0 (8/10) 100.0 (4/4) 90.0 (9/10)

Next: 2 Dose DALVANCE

DALVANCE CONNECTS

DALVANCE CONNECTS is a dedicated service to assist healthcare providers and patients with reimbursement support. For assistance, please call 1.855.387.2824.

INDICATION & USAGE

DALVANCE® (dalbavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus) and Enterococcus faecalis (vancomycin-susceptible strains).

To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial agents, DALVANCE should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

IMPORTANT SAFETY INFORMATION
Contraindications

DALVANCE is contraindicated in patients with known hypersensitivity to dalbavancin.

Warnings and Precautions

Hypersensitivity Reactions

Serious hypersensitivity (anaphylactic) and skin reactions have been reported with glycopeptide antibacterial agents, including DALVANCE. Exercise caution in patients with known hypersensitivity to glycopeptides due to the possibility of cross-sensitivity. If an allergic reaction occurs, treatment with DALVANCE should be discontinued.

Infusion-related Reactions

Rapid intravenous infusion of DALVANCE can cause reactions, including flushing of the upper body, urticaria, pruritus, and rash.

Hepatic Effects

ALT elevations with DALVANCE treatment were reported in clinical trials.

Clostridium difficile-associated Diarrhea

Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.

Development of Drug-resistant Bacteria

Prescribing DALVANCE in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Adverse Reactions

The most common adverse reactions in patients treated with DALVANCE were nausea (4.7%), headache (3.8%), and diarrhea (3.4%).

Use in Specific Populations

Please see Full Prescribing Information.

Privacy Statement and Terms of Use | Legal Notice

IMPORTANT SAFETY INFORMATION
Contraindications

DALVANCE is contraindicated in patients with known hypersensitivity to dalbavancin.

Show More
Warnings and Precautions

Hypersensitivity Reactions

Serious hypersensitivity (anaphylactic) and skin reactions have been reported with glycopeptide antibacterial agents, including DALVANCE. Exercise caution in patients with known hypersensitivity to glycopeptides due to the possibility of cross-sensitivity. If an allergic reaction occurs, treatment with DALVANCE should be discontinued.

Infusion-related Reactions

Rapid intravenous infusion of DALVANCE can cause reactions, including flushing of the upper body, urticaria, pruritus, and rash.

Hepatic Effects

ALT elevations with DALVANCE treatment were reported in clinical trials.

Clostridium difficile-associated Diarrhea

Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.

Development of Drug-resistant Bacteria

Prescribing DALVANCE in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Adverse Reactions

The most common adverse reactions in patients treated with DALVANCE were nausea (4.7%), headache (3.8%), and diarrhea (3.4%).

Use in Specific Populations
  • There have been no adequate and well-controlled studies with DALVANCE in pregnant or nursing women. DALVANCE should only be used if the potential benefit justifies the potential risk in these populations.
  • In patients with renal impairment whose known creatinine clearance is less than 30 mL/min and who are not receiving regularly scheduled hemodialysis, the recommended regimen of DALVANCE is 1125 mg, administered as a single dose, or 750 mg followed one week later by 375 mg. No dosage adjustment is recommended for patients receiving regularly scheduled hemodialysis, and DALVANCE can be administered without regard to the timing of hemodialysis.
  • Caution should be exercised when prescribing DALVANCE to patients with moderate or severe hepatic impairment (Child-Pugh Class B or C) as no data are available to determine the appropriate dosing in these patients.

Please see Full Prescribing Information.